EUCTR2010-019072-68-GB进行中（未招募）不适用
A randomised, double blind, crossover study to determine the mechanism of action of Gaviscon Advance in Gastro-Oesophageal Reflux Disease (GORD) - Gaviscon Advance
Guy's & St Thomas' NHS Foundation Trust0 个研究点目标入组 0 人开始时间: 2010年12月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Between 18 and 65 years of age
- •-History of reflux symptoms (heartburn, acid regurgitation, chest pain) requiring referral for oesophageal manometry and pH studies.
- •-Patients with chronic cough or dental problems are not excluded from the trial; however typical reflux symptoms must be present also. This is because there is little evidence that reflux events are responsible for symptoms in this group.31
- •-Provision of written, fully informed consent to undergo mechanistic study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •--Significant gastrointestinal symptoms or disease other than reflux
- •-Large hiatus hernia (>3cm)
- •-Severe reflux oesophagitis or Barrett’s oesophagus on endoscopy (LA grade III-IV).
- •-Previous upper GI surgery or interventions such as oesophageal dilatations
- •-Predominant symptoms of motility disorders, e.g. dysphagia
- •-Presence of major oesophageal dysmotility on manometry, e.g. achalasia, diffuse spasm, aperistalsis (>80% swallows)
- •-Significant co-morbidity requiring ongoing treatment or investigation
- •-Physical, neurological or psychiatric conditions preventing repeated visits to hospital or compliance with study procedures (e.g. physical impairment / reduced mobility)
- •-Pregnancy or lactation at the time of enrolment
研究者
相似试验
进行中（未招募）
1 期
Effect of tiotropium + olodaterol on breathlessness in COPD patientsPatients with moderate to severe Chronic Obstructive Pulmonary Disease according to the GOLD guidelines.MedDRA version: 19.0Level: LLTClassification code 10009026Term: Chronic obstructive airways diseaseSystem Organ Class: 100000004855EUCTR2015-002974-20-BESCS Boehringer Ingelheim Comm. V102
进行中（未招募）
1 期
Effect of tiotropium + olodaterol on breathlessness in COPD patientsPatients with moderate to severe Chronic Obstructive Pulmonary Disease according to the GOLD guidelines.MedDRA version: 19.0Level: LLTClassification code 10009026Term: Chronic obstructive airways diseaseSystem Organ Class: 100000004855EUCTR2015-002974-20-NLBoehringer Ingelheim bv130
已完成
4 期
A randomised, double-blind, cross-over study to evaluate the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (5/5 µg) compared with tiotropium (5 µg), both delivered by the Respimat® Inhaler, on breathlessness during the three minute Constant Speed Shuttle Test (3min CSST) in patients with Chronic Obstructive Pulmonary Disease (COPD).COPD (Chronic Obstructive Pulmonary Disease10038716NL-OMON42990Boehringer Ingelheim18
进行中（未招募）
不适用
A randomised, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPDChronic Obstructive Pulmonary DiseaseEUCTR2008-000725-18-GBGlaxoSmithKline Reaseach & Development45
已完成
不适用
A double-blind, randomised, crossover study to investigate the difference in frequency of episodes of hypoglycaemia during treatment with Biphasic Insulin Aspart 30 (NovoMix®30) compared to Biphasic Human Insulin 30 (Mixtard® 30) in patients with well-controlled, type 2 diabetesType 2 diabetes requiring insulinNutritional, Metabolic, EndocrineDiabetesISRCTN34091554ovo Nordisk Ltd (UK)160